Cantor Fitzgerald's Rare Orphan Disease Summit: The company will participate in a panel presentation on Wednesday, March 30, 2022, at 4:00 p. ET, titled, "Cell Therapy: How the Definition Has Expanded With Time, and the Potential Applications For Rare Diseases. Time: 3:45 - 4:25 p. m. (ET). Webcasts for these conferences will be available in the "Events & Media" section of the Taysha corporate website at. Oppenheimer rare & orphan disease summit. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
For more information, please visit Contacts. Governance Highlights. 2020 Biotech Showcase Conference. Format: 40-minute live virtual presentation. Date: Time: Format: Fireside chat. AUSTIN, Texas--( BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT. Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). SOURCE Regulus Therapeutics Inc. Announces Participation at Upcoming Investor Conferences. 2021 RBC Capital Markets Global Healthcare Conference. About Casma Therapeutics. Site - Shareholder Tools. LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph. Vanda is developing important new medicines to improve the lives of patients. Company Contacts: Jaclyn Jaffe and Bill Begien.
UBS Global Healthcare Virtual Conference. Savara Inc. at at 28th Annual Oppenheimer & Co. Healthcare Conference. The company has initiated a Phase 3 trial in refractory status epilepticus. VirtualA replay of the virtual presentation is accessible until October 12, 2022.
60th European Society for Paediatric Endocrinology (ESPE) Meeting. Executive Vice President, CFO. Vanda Pharmaceuticals Inc. (202) 734-3400. Date and Time: Monday, May 24, 8:00 a. m. ET. For more information on Harmony, please visit the company's website: Harmony Biosciences Investor Contact: Lisa Caperelli. Oppenheimer rare and orphan disease summit entertainment. ERS Congress (This is not a webcast event. Archived versions of the webcasts will be available on the website for 60 days.
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. JMP Securities Life Sciences Conference. Stifel 2019 Healthcare Conference. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. All of the above webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, About Marinus Pharmaceuticals. Mustang Bio to Participate in Three March 2022 Investor Conferences :: (MBIO. Investors: MeiraGTx. Cellectar Biosciences, Inc. Home. January 18, 2023Sidoti Small-Cap Virtual Investor Conference.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences: B. Riley Neuroscience Conference. Jefferies 2017 London Healthcare Conference. Details are as follows: Date: Friday, May 21, 2021. A live webcast of the presentation will be available on the investor relations section of the Company's website at. Courteney Backstrom. Details of the events are as follows: - Oppenheimer's 32 nd Annual Virtual Healthcare Conference: The company will participate in a fireside chat on Tuesday, March 15, 2022, at 4:00 p. m. ET and will participate in one-on-one meetings during the conference. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's. CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit. That is, maintaining the same high standards throughout the entire product development process, and never losing sight of our ultimate goal–improving patients' lives. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
The platform, comprised of a family of over 160 engineered peptides, leverages one billion years of evolution that has enabled the human astrovirus to inhibit components of the innate immune system. May 1, 2022 2:30 pm EDT. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. H. Wainwright Virtual Investment Conference. Norfolk, VA, February 22, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled to participate in the upcoming Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. Oppenheimer rare and orphan disease summit 2017. Media: Real Chemistry. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency.
Governance Documents. Source: Marinus Pharmaceuticals. March 15 – 20, 2022AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. Dr. Thienel will meet with potential investors, partners, and other collaborators to discuss the development of ReAlta's dual-targeting peptide technology platform to deliver game-changing new therapies for hypoxic-ischemic encephalopathy (HIE) and other life-threatening rare diseases. For members of the press or investor community who wish to obtain more information about Vanda, please contact: Senior Vice President, Chief Financial Officer and Treasurer.
keepcovidfree.net, 2024